Summary

The 7 major urinary retention markets reached a value of US$ 2.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.8 Billion by 2034, exhibiting a growth rate (CAGR) of 6.23% during 2024-2034.

The urinary retention market has been comprehensively analyzed in IMARC’s new report titled “Urinary Retention Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Urinary retention refers to a type of condition wherein the patient is unable to release all the urine from the bladder. Although this is not considered as a disease, it signifies other related health disorders, such as prostate problems in men and cystoceles in women. Various urinary retention symptoms include the inability to urinate, severe pain in the lower abdomen, the urge to urinate, swelling caused in the lower abdomen, etc. The diagnosis of urinary retention consists of a physical examination, including checking the lower abdominal region, a rectal examination, and a neurological evaluation. In the case of females, a pelvic exam is also carried out. Furthermore, postvoid residual urine measurement is done, thereby indicating the amount of urine that is left in the bladder after urination.

The rising incidences of bladder dysfunction on account of the escalating urological disorders are primarily driving the global urinary retention market. In addition to this, the expanding geriatric population, who are more susceptible to such ailments, is further creating a positive outlook for the market. Moreover, the increasing number of surgical procedures that involve the use of anesthesia, which deprives patients of the need to urinate despite having a full bladder, is also bolstering the market growth. Besides this, the inflating number of educational initiatives to teach self-catheterization in home care settings is further acting as a significant growth-inducing factor. Additionally, continuous technological advancements, including the introduction of advanced intermittent catheters with specialized material coatings that provide resistance against microorganisms, are also propelling the global market. Apart from this, the emerging popularity of physical therapy, such as pelvic floor exercises or Kegel exercises, which aid in improving bladder function and help to prevent urinary retention, is positively influencing the market growth. Numerous other factors, including the ongoing upgradation of healthcare infrastructures and the implementation of favorable health management programs, are expected to drive the global urinary retention market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the Urinary Retention market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Urinary Retention and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Urinary Retention market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Urinary Retention market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Urinary Retention market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Urinary Retention marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Urinary Retention market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Urinary Retention market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Urinary Retention market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the size of the Urinary Retention patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Urinary Retention?
What will be the growth rate of patients across the seven major markets?

Urinary Retention: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Urinary Retention drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Urinary Retention market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Urinary Retention - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.3 Market Overview (2018-2023) and Forecast (2024-2034​)
4.4 Competitive Intelligence

5 Urinary Retention - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Urinary Retention - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)

8 Urinary Retention - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Urinary Retention - Unmet Needs

10 Urinary Retention - Key Endpoints of Treatment

11 Urinary Retention - Marketed Products
11.1 List of Urinary Retention Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Urinary Retention - Pipeline Drugs
12.1 List of Urinary Retention Pipeline Drugs Across the Top 7 Markets
12.1.1 Sugammadex - Merck Sharp & Dohme LLC
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Urinary Retention - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Urinary Retention - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Urinary Retention - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034​)
14.2.2 Urinary Retention - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034​)
14.3 Market Scenario - United States
14.3.1 Urinary Retention - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034​)
14.3.2 Urinary Retention - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034​)
14.3.3 Urinary Retention - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Urinary Retention - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034​)
14.4.2 Urinary Retention - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034​)
14.4.3 Urinary Retention - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Urinary Retention - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034​)
14.5.2 Urinary Retention - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034​)
14.5.3 Urinary Retention - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Urinary Retention - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034​)
14.6.2 Urinary Retention - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034​)
14.6.3 Urinary Retention - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Urinary Retention - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034​)
14.7.2 Urinary Retention - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034​)
14.7.3 Urinary Retention - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Urinary Retention - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034​)
14.8.2 Urinary Retention - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034​)
14.8.3 Urinary Retention - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Urinary Retention - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034​)
14.9.2 Urinary Retention - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034​)
14.9.3 Urinary Retention - Access and Reimbursement Overview

15 Urinary Retention - Recent Events and Inputs From Key Opinion Leaders

16 Urinary Retention Market - SWOT Analysis

16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix